Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | NILK-2301 |
Trade Name | |
Synonyms | NILK2301|NILK 2301 |
Drug Descriptions |
NILK-2301 is a bispecific antibody that targets CEACAM5 expressed on tumor cells and CD3 on T-cells, which induces T-cell activation, potentially leading to cytotoxicity in CEACAM-expressing tumor cells and tumor growth inhibition (PMID: 38087365). |
DrugClasses | CD3 Antibody 99 CEACAM5 Antibody 8 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
NILK-2301 | NILK-2301 | 0 | 1 |
NILK-2301 + Pembrolizumab | NILK-2301 Pembrolizumab | 0 | 0 |